+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Distribution of ovarian cancer recurrence following intravenous (IV) and intraperitoneal (IP) adjuvant chemotherapy after upfront cytoreductive surgery



Distribution of ovarian cancer recurrence following intravenous (IV) and intraperitoneal (IP) adjuvant chemotherapy after upfront cytoreductive surgery



Gynecologic Oncology 133: 70-71




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 064467379

Download citation: RISBibTeXText

DOI: 10.1016/j.ygyno.2014.03.190


Related references

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later?. European Journal of Surgical Oncology 39(10): 1109-1115, 2013

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecologic Oncology 122(2): 215-220, 2011

Complications associated with 9-10Fr venous access port use in adjuvant intraperitoneal chemotherapy after a cytoreductive surgery in ovarian cancer patients. Advances in Medical Sciences 60(2): 216-219, 2016

Upfront compared to delayed cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei is associated with considerably lower perioperative morbidity and recurrence rate. Annals of Surgery 253(4): 769-773, 2011

Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis. European Journal of Surgical Oncology 45(3): 301-309, 2019

Obesity does not influence the decision between neoadjuvant chemotherapy and upfront cytoreductive surgery in advanced ovarian cancer. Gynecologic Oncology 141: 100-101, 2016

HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy. Gynecologic Oncology 149(1): 155-162, 2018

Establishing evidence for change in ovarian cancer surgery--proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis. Gynecologic Oncology 115(1): 166-168, 2009

Cytoreductive surgery and perioperative intraperitoneal chemotherapy in recurrent ovarian cancer. Tumori 96(3): 411-416, 2010

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer. International Journal of Hyperthermia 32(3): 298-310, 2017

Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. Journal of Surgical Oncology 98(4): 283-290, 2008

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for First Relapse of Ovarian Cancer. Anticancer Research 35(9): 4997-5005, 2016

Peritoneal carcinomatosis from ovarian cancer: cytoreductive surgery and intraperitoneal chemotherapy. Journal of ChemoTherapy 11(3): 239-240, 1999

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World Journal of Surgical Oncology 2: 21, 2004

Splenectomy in Cytoreductive Surgery for Advanced Ovarian Cancer and Subsequent Intraperitoneal Chemotherapy. Journal of Gynecologic Surgery 26(3): 179-182, 2010